Also, high KMT2A expression predicted poor survival in hepatocellular carcinoma, and melanoma patients [57, 60], demonstrating the potential clinical benefit of KMT2A degradation in both KMT2A‐r and wild‐type patients. The gene discussed is KMT2A; the disease is hepatocellular carcinoma.